Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers

Recently, long intergenic non-protein coding RNA 01133 (LINC01133) was identified as a novel transcript in cancers. It modulates various hallmarks of cancers and acts as oncogenic in some cancers while tumor-suppressive in others. Furthermore, the expression of LINC01133 correlates with tumor size, advanced tumor node metastasis stage and lymphatic node metastasis, Ki-67 levels and overall survival of patients. Herein, the authors provide an in-depth analysis describing how LINC01133 modulates the multiple cancer-associated signaling pathways and the pathogenesis of various malignancies and treatment regimens. Based on the role played by LINC01133, the authors propose LINC01133 as both a potential biomarker and a therapeutic target in cancer.

Automated summary

LINC01133 has been identified as a novel transcript in cancers, playing a significant role in modulating various cancer hallmarks. It serves as both an oncogenic and tumor-suppressive factor in different types of cancers. The expression of LINC01133 is correlated with tumor characteristics and patient survival. The authors propose LINC01133 as a potential biomarker and therapeutic target in cancer.